Life Science Innovation Network Japan (LINK-J) launched the partnering event series “Advanced Therapy Showcase in Tokyo (ATST)” in January 2021. Following two successful events, we are pleased to announce that the third edition of the series, the ATST#3, is slated for Wednesday, 1 February 2023. Its format will be the same as its precedents, a virtual event featuring live-streaming, company presentations and pre-arranged one-on-one business partnering meetings. The partnering will be open on the five weekdays of the week.
Any entities or individuals engaged in the field of advanced therapy including but not limited to cell & gene therapy, regenerative medicine, nucleic acid medicine, etc. are encouraged to participate in this event to find suitable and relevant partner candidates for their business endeavors.
Product developers, novel technology providers, platform developers, and researchers who seek partners in Japan or elsewhere, and crave to excel in the field of advanced therapies such as;Any parties who are interested in partnering with product developers, novel technology providers, platform developers, and researchers who seek partners in Japan or elsewhere, and crave to excel in the field of advanced therapies such as;
regenerative medicine and tissue engineering,
cell therapy and gene-modified cell therapy,
gene therapy (in vivo/ex vivo) and gene editing therapy,
exosome based therapy,
nucleic acid medicine,
stem cell based drug discovery, etc.
Progenicyte Japan Co., Ltd.
Celaid Therapeutics Inc.
Delta-Fly Pharma, Inc.
Elixirgen Scientific Japan, Inc.
iHeart Japan Corp.
Luxna Biotech Co., Ltd.
Minaris Regenerative Medicine Co., Ltd.
Stempeutics Research Pvt. Ltd.
eTheRNA Immunotherapies NV
PDC*line pharma SA
Eligo Biosicience SAS
TreeFrog Therapeutics SAS
Salipro Biotech AB
Orchard Therapeutics plc
Laverock Therapeutics Ltd.
Touchlight DNA Services Ltd.